Mesintel Therapeutics
1 known investors
Mesintel develops a proprietary target discovery platform based on fibroblast biology to accelerate drug development in cancer, fibrosis, rare diseases, tissue regeneration, and aging-related conditions. The company uses single-cell multi-omics, genetically engineered models, and AI/ML to identify novel therapeutic targets.
Founders & leadership
TM
T. Michael UnderhillCo-founder, Chief Executive Officer and Chief Scientific Officer
LH
Lesley HillCo-founder, Chief Operating Officer
RW
R. Wilder ScottCo-founder, Chief Technology Officer
JJ
Jonathon JafariCo-founder, Chief Business Officer
Investors · 1
Frequently asked questions
- What does Mesintel Therapeutics do?
- Mesintel develops a proprietary target discovery platform based on fibroblast biology to accelerate drug development in cancer, fibrosis, rare diseases, tissue regeneration, and aging-related conditions. The company uses single-cell multi-omics, genetically engineered models, and AI/ML to identify novel therapeutic targets.
- Who founded Mesintel Therapeutics?
- Mesintel Therapeutics was founded by T. Michael Underhill, Lesley Hill, R. Wilder Scott, Jonathon Jafari.
- Who are Mesintel Therapeutics's investors?
- Mesintel Therapeutics's investors include Innovation UBC.